Published in Aliment Pharmacol Ther on April 03, 2014
Editorial: safety and tolerability of rifaximin for IBS - more information is required. Aliment Pharmacol Ther (2014) 1.06
Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry (2015) 0.96
New and Emerging Treatment Options for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.91
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med (2016) 0.86
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol (2016) 0.85
Structural basis of rifampin inactivation by rifampin phosphotransferase. Proc Natl Acad Sci U S A (2016) 0.83
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol (2015) 0.81
Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clin Transl Gastroenterol (2016) 0.80
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol (2016) 0.75
Rifaximin: irritable bowel syndrome. Hosp Pharm (2014) 0.75
Microbiome Changes during Tuberculosis and Antituberculous Therapy. Clin Microbiol Rev (2016) 0.75
Editorial: safety and tolerability of rifaximin for IBS - more information is required; authors' reply. Aliment Pharmacol Ther (2014) 0.75
Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: a proof-of-concept study. Therap Adv Gastroenterol (2015) 0.75
Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes (2016) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Current status of Clostridium difficile infection epidemiology. Clin Infect Dis (2012) 3.14
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy (2005) 1.27
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci (2007) 1.26
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis (2006) 1.21
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother (2011) 1.18
Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol (2009) 1.15
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect (2004) 1.14
Antibiotic therapy for the irritable bowel syndrome. N Engl J Med (2011) 1.09
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther (2012) 1.03
Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther (2012) 1.02
Current state of Clostridium difficile treatment options. Clin Infect Dis (2012) 1.02
Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol (2007) 0.99
Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y) (2011) 0.97
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med (2012) 0.94
Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res (1986) 0.93
In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother (2012) 0.90
Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol (2010) 0.90
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother (2012) 0.90
Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study. Gastroenterol Res Pract (2011) 0.87
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A (1990) 14.22
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
The RNA component of human telomerase. Science (1995) 9.86
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut (2009) 8.98
Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature (1996) 7.90
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev (1998) 6.74
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Selective solubilization of proteins from red blood cell membranes by protein perturbants. J Supramol Struct (1973) 5.18
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
A second chromosomal gene necessary for intimate attachment of enteropathogenic Escherichia coli to epithelial cells. J Bacteriol (1993) 5.02
Selective solubilization of proteins and phospholipids from red blood cell membranes by nonionic detergents. J Supramol Struct (1973) 4.95
Applications of ultrasonography in the reproductive management of Dux magnus gentis venteris saginati. Vet Rec (2007) 4.50
Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry (2001) 4.37
Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry (2001) 4.13
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Effect of gestational age on obstetric performance: when is "term" over? Lancet (1991) 3.96
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest (2001) 3.86
Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci (2001) 3.46
Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther (2012) 3.35
Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell (1995) 3.34
Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun (2001) 3.28
Cell-cycle arrest versus cell death in cancer therapy. Nat Med (1997) 3.18
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst (1999) 2.99
c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet (1999) 2.95
Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation (1998) 2.90
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol (1998) 2.81
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Double echo steady state magnetic resonance imaging of knee articular cartilage at 3 Tesla: a pilot study for the Osteoarthritis Initiative. Ann Rheum Dis (2005) 2.76
JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity (1999) 2.74
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther (2005) 2.71
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev (1999) 2.56
Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil (2013) 2.53
Isolation and characterization of new fission yeast cytokinesis mutants. Genetics (1998) 2.51
Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res (2001) 2.51
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med (2001) 2.47
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med (2000) 2.44
Modification of lignin biosynthesis in transgenic Nicotiana through expression of an antisense O-methyltransferase gene from Populus. Plant Mol Biol (1994) 2.42
Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A (2001) 2.40
Multiple-complete-digest restriction fragment mapping: generating sequence-ready maps for large-scale DNA sequencing. Proc Natl Acad Sci U S A (1997) 2.36
The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2013) 2.30
Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA (2000) 2.29
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology (2000) 2.26
MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene (2010) 2.23
V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2001) 2.19
Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem (1988) 2.19
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev (2001) 2.16
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem (2001) 2.14
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) (2006) 2.13
Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst (2001) 2.12
Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem (1994) 2.07
White-light filaments for atmospheric analysis. Science (2003) 2.07
Reconstitution of intramembrane particles in recombinants of erythrocyte protein band 3 and lipid: effects of spectrin-actin association. Proc Natl Acad Sci U S A (1976) 2.07
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther (2008) 2.06
Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res (2001) 2.05
High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis (2013) 2.02
How does the mode of delivery affect the cost of maternity care? Br J Obstet Gynaecol (1991) 1.97
Prospective comparison treatment of 595-nm pulsed-dye lasers for virgin port-wine stain. Br J Dermatol (2015) 1.96
Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology (1997) 1.94
mRNA stabilization by the ompA 5' untranslated region: two protective elements hinder distinct pathways for mRNA degradation. RNA (1998) 1.89
Leisure-time physical activity, television watching, and plasma biomarkers of obesity and cardiovascular disease risk. Am J Epidemiol (2000) 1.89
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer (2009) 1.88
Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem (1990) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol (2000) 1.85
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene (2006) 1.82
Pathogenesis of the Segond fracture: anatomic and MR imaging evidence of an iliotibial tract or anterior oblique band avulsion. Radiology (2001) 1.82
PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ (2009) 1.81
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997) 1.78
The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther (2004) 1.76
Lower diffusion in white matter of children with prenatal methamphetamine exposure. Neurology (2009) 1.76
Apoptosis: an early event in metastatic inefficiency. Cancer Res (2001) 1.74
Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol (2007) 1.73
Assembly of high-resolution restriction maps based on multiple complete digests of a redundant set of overlapping clones. Genomics (1996) 1.72
Two year longitudinal change and test-retest-precision of knee cartilage morphology in a pilot study for the osteoarthritis initiative. Osteoarthritis Cartilage (2007) 1.71
Increased expression of Aspergillus parasiticus aflR, encoding a sequence-specific DNA-binding protein, relieves nitrate inhibition of aflatoxin biosynthesis. Appl Environ Microbiol (1995) 1.66
Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation (1998) 1.65
Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther (2007) 1.65
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther (2014) 1.64
New genotype of avian influenza H5N1 viruses isolated from tree sparrows in China. J Virol (2005) 1.64
Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med (2001) 1.64
Characterization of newly emerging Newcastle disease virus isolates from the People's Republic of China and Taiwan. J Clin Microbiol (2001) 1.63
Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther (2011) 1.63
A matter of time: evaluating the storage of fecal samples for steroid analysis. Gen Comp Endocrinol (2002) 1.62
The role of the sid1p kinase and cdc14p in regulating the onset of cytokinesis in fission yeast. EMBO J (2000) 1.62
Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology (2002) 1.61
The autophagic paradox in cancer therapy. Oncogene (2011) 1.61